NCI Explores AI to Screen For and Treat Pancreatic Cancer
The institute sees the emerging technology supporting treatment for patients by better controlling tumor growth.
A new initiative at the National Cancer Institute aims to create capabilities for detecting pancreatic cancer early and improving treatments for patients with mutations.
A big challenge with pancreatic cancer resides in the KRAS gene. When mutated, the gene can cause normal cells to become cancerous. A new therapy involving KRAS inhibitors and genetic testing can help patients screen for this earlier.
Dr. Christine Alewine, the NIH Lasker Scholar in the Laboratory of Molecular Biology at NCI’s Center for Cancer Research, discussed this breakthrough, how new advancements can serve as an alternative treatment for chemotherapy and where AI can make an impact. Plus, she notes how other health issues such as diabetes also plays a role in screening for pancreatic cancer.
-
Dr. Christine Alewine NIH Lasker Scholar in the Laboratory of Molecular Biology, Center for Cancer Research NCI
-
Cyber Experts Highlight Zero Trust's Role Against AI Threats
Experts share why zero trust principles and cyber hygiene practices are key to combatting the growing threat of frontier AI models.
2m read -
DOE Looks to AI to Advance Next Generation of Quantum
Experts explain how the Genesis Mission will merge AI and quantum to further scientific discovery and research.
3m read -
One Year Later: Agencies Turn AI Action Plan Into Federal Programs
Since the White House released its AI strategy, federal agencies are deploying tools and programs to expand AI capabilities.
3m read -
White House Lays Out 'Golden Age' AI Vision for American Science
The blueprint emphasizes artificial intelligence, research funding reforms and mission-driven innovation to reshape federal research.
3m read
